Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levodropropizine + bromhexine hydrochloride
- Development stage
- Unknown
- Lead developer
- Korea Arlico Pharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALC-2209 is an improved new drug (fixed-dose combination) developed by Korea Arlico Pharm for the treatment of respiratory diseases, particularly acute bronchitis. It combines levodropropizine, a peripheral antitussive that suppresses the cough reflex by inhibiting sensory neuropeptide release in the airways, with bromhexine hydrochloride, a mucolytic agent that reduces the viscosity of phlegm to facilitate expectoration. This combination aims to provide synergistic relief for patients suffering from cough and excessive bronchial secretions. As of 2024, the candidate is in Phase 3 clinical trials in South Korea.
- Other names
- levodropropizine/bromhexine
02
Targets
TMPRSS2 (Transmembrane protease serine 2)ACE2 (Angiotensin-converting enzyme 2)
Beyond the preview
Go deeper on levodropropizine + bromhexine hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levodropropizine + bromhexine hydrochloride.